Duloxetine + placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Osteoarthritis Knee Pain
Conditions
Osteoarthritis Knee Pain
Trial Timeline
Nov 1, 2006 → Oct 1, 2007
NCT ID
NCT00408421About Duloxetine + placebo
Duloxetine + placebo is a phase 3 stage product being developed by Eli Lilly for Osteoarthritis Knee Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00408421. Target conditions include Osteoarthritis Knee Pain.
What happened to similar drugs?
20 of 20 similar drugs in Osteoarthritis Knee Pain were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01931475 | Phase 3 | Completed |
| NCT01451606 | Approved | Terminated |
| NCT01226511 | Phase 3 | Completed |
| NCT01179672 | Phase 3 | Completed |
| NCT01237587 | Phase 3 | Completed |
| NCT01118780 | Approved | Completed |
| NCT01070329 | Approved | Completed |
| NCT01000805 | Approved | Completed |
| NCT01018680 | Phase 3 | Completed |
| NCT00965081 | Approved | Completed |
| NCT00803361 | Phase 3 | Completed |
| NCT00767806 | Phase 3 | Completed |
| NCT00433290 | Phase 3 | Completed |
| NCT00424593 | Phase 3 | Completed |
| NCT00457730 | Phase 2/3 | Completed |
| NCT00408876 | Phase 3 | Completed |
| NCT00408421 | Phase 3 | Completed |
| NCT00607789 | Approved | Completed |
| NCT00375973 | Phase 2/3 | Completed |
| NCT00233025 | Phase 3 | Completed |
Competing Products
20 competing products in Osteoarthritis Knee Pain